Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
Jinpeng Cen, Jiading Guo, Xianzi Zeng, Xianlu Song, Shengdong Ge, Mingkun Chen, Qianyi Li, Yuzhong Yu, Daojun Lv, Shanchao Zhao
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsProstate Cancer Treatment and Research
In the published article, there was an error in the legend for Figure 3E. Due to an oversight, the IC50 value for LNCaP-NC was incorrectly reported as:
“LNCaP-NC: 21.03 µM, 95% CI: 19.62–22.36.”
The corrected legend appears below.
“LNCaP-NC: 51.15 µM, 95% CI: 47.92–54.33.”
The authors apologize for this error and confirm that it does not affect the scientific conclusions of the article. The original article has been updated accordingly.
In the published article, there was an error in Figure 3E as presented. The visualization results for Figure 3E were correctly submitted and approved during the first round of revisions. However, due to an oversight on our part, this figure was inadvertently omitted in the second revised version. The corrected Figure 3E and its accompanying caption—Figure 3 ELOVL2 inhibition suppresses growth and restores enzalutamide sensitivity in resistant PCa cells—are provided below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.